Nutlin-3

Catalog No.S1061

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Price Stock Quantity  
USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nutlin-3 Chemical Structure

Nutlin-3 Chemical Structure
Molecular Weight: 581.5

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

Nutlin-3 is available in the following compound libraries:

Product Information

  • Compare Mdm2 Inhibitors
    Compare Mdm2 Products
  • Research Area

Product Description

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets Mdm2 [1]
(Cell-free assay)
IC50 90 nM
In vitro Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MCF7M2HDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVq1xsDPxE1?MWS0POKhcA>?NYradFZo[myxY3vzJFI4NU:KQz3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDjc41x[XKjYnzlJJRwKHSqYYSgc4Yh[mG|YXygcIV3\Wy|M4f1OFI3OzVyNU[1
NP69MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vwcGlEPTB;M{GuOlnDuTJwNUSg{txONWjSb5VtOjZ{NUK1O|U>
NP460NXLnU|lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnmTWM2OD1{Mj64OeKyOS5zODFOwG0>MoL2NlYzPTJ3N{W=
C666-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDrTWM2OD1zOT65OeKyQC57MzFOwG0>NGDvWIozPjJ3MkW3OS=>
C666-1M2ToUGNmdGxiVnnhZoltcXS7IFHzd4F6MnrsNVAhyrWPMV20PEBpMlHSSG1UVw>?NF;hSWl{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDjbZNxdGG2aX6=NWDwXpYxOjZ{NUK1O|U>
C666-1 M{nJNWZ2dmO2aX;uJGF{e2G7M1q5T|ExKML3TR?=Mn[xNlQhcA>?NVvjSHB3TE2VTx?=M1LOPYFkfGm4YYTld{B1cGVicEWzJJBifGi5YYmsJJVxemWpdXzheIlv\yCyNUOsJJAzOSCjbnSgUYRuOg>?NYnVNJFvOjZ{NUK1O|U>
C666-1NHvrRXZCeG:ydH;zbZMhSXO|YYm=NWH1Smp[OTBiwsXNNWXPNItvPDhxN{KgbC=>M1m4UWROW09?MkDld4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:gZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nzM{TpSVI3OjV{NUe1
A549M3jid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrHNlQhcA>?NYPBcVhwUUN3ME2xO{43QCEEsTC0MlUzKM7:TR?=M4TNU|I3OTJ3MkOw
A549-NTCM4jUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWiyOEBpMoLwTWM2OD1zOT60NkDDuSBzLkm2JO69VQ>?MYCyOlEzPTJ|MB?=
A549-920MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmGxNlQhcA>?NHTMfZZKSzVyPUOzMlg2KMLzIESuPFQh|ryPNUDsfohwOjZzMkWyN|A>
CRL-5908NXjwbJJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILScYUzPCCqMnvYTWM2OD1|OD63NUDDuSB{LkSzJO69VQ>?MWKyOlEzPTJ|MB?=
L6NVXkTosxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrXUGsyOMLizszNxsA>MYOyOE81QC95MjDoM{nrbWROW09?NEO4c2ZqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25?MlHiNlU5PzF5OUS=
C2C12MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIn0TZIyOMLizszNxsA>NXL5c4xJOjRxNEivO|IhcA>?MlzRSG1UVw>?NGT3RW5qdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25?M4O2PVI2QDdzN{m0
MCF-7 NXflNoJVTnWwY4Tpc44hSXO|YYm=NEHFSpAyOMLizszNNITpOmNFVVORNXS0foxtcW6qaXLpeJMh[3mlbHnuJGQyKGGwZDDEbYNmesLiM{m2VFI2PzB{N{Cz
DU4475 MVzGeY5kfGmxbjDBd5NigQ>?NHfubXE2NzFyL{KwJO69VQ>?NUe1TlQ1OjUEoHi=MYjkc5dvemWpdXzheIV{KFSxY3GtNUBld3OnIHTldIVv\GWwdHz5NGXleYszPTV2N{G3OC=>
SMMC-7721NUD3fmY2TnWwY4Tpc44hSXO|YYm=MXmxNEDPxE1?M1:1XlQ5KGh?M4fITGROW09?NEXiT3Rk[XW|ZYOgSG5CKESVQjDkZY1i\2V?MYmyOVU1PDN4MR?=
SMMC-7721NYH6dG5qTnWwY4Tpc44hSXO|YYm=NFS0OIsyOCEQvF2=M4[4RVQ5KGh?NX\QfFdQTE2VTx?=NH;ZPXZqdmS3Y3XzJJRp\SClaILvcYF1cW5vYn;1coQheHKxdHXpckBKTklzNjD0c{Bx[XK2aXHscJkhdG:lYXzpfoUhcW5idHjlJIN6fG:ybHHzceKhNUDuNmg{OjV3NESzOlE>
SMMC-7721MnTKSpVv[3Srb36gRZN{[Xl?NXK2RZZ[OTBizszNMlSwOFghcA>?NV;tR3UzTE2VTx?=MXfpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2cEoFnGUmIyyqCvUl7BMYqyOVU1PDN4MR?=
SMMC-7721MWfGeY5kfGmxbjDBd5NigQ>?MW[xNEDPxE1?MWSzOkBpNU\BV4s5TE2VTx?=MoX3Z4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY>MV[yOVU1PDN4MR?=
MCF-7M{LVNGZ2dmO2aX;uJGF{e2G7M1fJZ|ExyqEQvF2=M4e1XlAuOjRiaB?=NELSVHJqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG=NXzSPZNpOjV2OEKzO|M>
OVCAR10MlHySpVv[3Srb36gRZN{[Xl?MnjDNVDDqM7:TR?=M4DvNVIycMLiMl7HSG1UVw>?MmTRbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=>NIDCUXgzPTR{NkW0PC=>
NCI-H23M{mxUmZ2dmO2aX;uJGF{e2G7NXLTVINKOTEEoN88US=>NWTJUI5wOjGqwrC=NIHhVpRFVVORMljLbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=>MlHnNlU1OjZ3NEi=
A2780NFPSTFdHfW6ldHnvckBCe3OjeR?=NX3HfWpxOTEEoN88US=>MVuyNYjDqA>?NFfsTFdFVVORNVnRPFJRcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>?NWS0N2ZOOjV2Mk[1OFg>
NCI-H23NFHwT29HfW6ldHnvckBCe3OjeR?=MkGwNVDDqM7:TR?=MXuyNYjDqA>?MVrEUXNQMn;q[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO=MVmyOVQzPjV2OB?=
A2780NX:1UZQ{TnWwY4Tpc44hSXO|YYm=NH\0OHcyOMLizszNNYrZcYpQOjGqwrC=NGTIU2FFVVORM2\OeYRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzzNWKyfVZMOjV2Mk[1OFg>
HCT116 MYXGeY5kfGmxbjDBd5NigQ>?M2jxSVExKML3TR?=NVTTN2N6OjRiaB?=MVjjZZV{\XNiYTDwOVMu\GWyZX7k[Y51KHSndILhdIxwcWRiR{GtZZJz\XO2IHnuJIRqeGyxaXSgTGNVOTF4IHPsc45meyCGMzDhcoQhTDh?MUGyOVM5ODB3NR?=
MCF-10CA1aMULGeY5kfGmxbjDBd5NigQ>?MmeyNVDDqM7:TR?=NXjvRmRbPDhiaB?=NXKyXGVtTE2VTx?=NXvNXIF2cW6qaXLpeJMh[mG|YXygbY53[XOrb36gZY5lKHKnZIXj[YQhXEeILd8yN{1qdmS3Y3XkJIlvfmG|aX;uJJRwKGKjc3HsJIxmfmWucx?=MkXoNlUzPTd5Mkm=
MCF-10A1 NUP5Xmg3TnWwY4Tpc44hSXO|YYm=MnTKNVDDqM7:TR?=MYOyOE81QCCqMWTEUXNQMW\pcohq[mm2czDtbYdz[XSrb36gc4Yhdm:{bXHsJIJz\WG|dDDldIl1cGWuaXHsxsA>MoLuNlUzPTd5Mkm=
MCF-10CA1aM2TPNGZ2dmO2aX;uJGF{e2G7MVWxNOKh|ryPMlzlNlQhcA>?MUnEUXNQMXrk[YNz\WG|ZYOgeIhmKFSJRj5OtlMucW6mdXPl[EBuWk6DIHzleoVteyCxZl3NVFItyqCPTWC5MEBidmUEoHnueIVoemmwwrFOtuKhOw>?NFfr[3MzPTJ3N{eyPS=>
MCF-10CA1aM{\kVGZ2dmO2aX;uJGF{e2G7MkDGNVDDqM7:TR?=MWmyOEBpMVfEUXNQM1vRZ4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?=NHLYPWwzPTJ3N{eyPS=>
SK-BR-7NFTWbnRHfW6ldHnvckBCe3OjeR?=MnXsNVDDqM7:TR?=MYOyOEBpNIXlR2hFVVORMUTpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25?MYKyOVI2Pzd{OR?=
SUM102PTMnTZSpVv[3Srb36gRZN{[Xl?NFi3NmQyOMLizszNMoL1NlQhcA>?M17LbmROW09?NXjFOmlXcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uNE\3ZpkzPTJ3N{eyPS=>
RAW 264.7NWHzfoh6TnWwY4Tpc44hSXO|YYm=NWW0WVRwOTEEoN88US=>M2DpU|MxKG2rbh?=M{jWPJBz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=>NIfIcVkzPTF5MkW0Oy=>
RAW 264.7NIH3NVFHfW6ldHnvckBCe3OjeR?=MV[xNOKh|ryPNWOwfFFqOzBibXnuMXzy[YR2[2W|IITo[UBNWFNvYYXncYVvfGWmIITo[UBPTi4QulKgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHjeIl3cXS7MVSyOVE4OjV2Nx?=
RAW 264.7M1PqZWZ2dmO2aX;uJGF{e2G7M2DXe|ExyqEQvF2=MVqzNEBucW5?Mn;pbY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMgMYmyOVE4OjV2Nx?=
MCF7 NH3lNmFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?MnvTNk42KML3TR?=MnLkOUBlM37kNWROW09?M{Xtc5NmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36=NVTRZ4MxOjVyOEW5NFI>
MCF7 NFuxNGxHfW6ldHnvckBCe3OjeR?=Mn\ENk42KML3TR?=M{LK[FQ5KGh?NIPZZ2ZFVVORNELWRnNl\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>?MlLsNlUxQDV7MEK=
ACHNM3fubWNmdGxiVnnhZoltcXS7IFHzd4F6NH;wRYMxNjVvMUCg{txOMUWwMVYh\A>?M2XY[mROW09?NEn5TI5qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{MoG4NlUxPjd5OEe=
Caki-2M{TXTmNmdGxiVnnhZoltcXS7IFHzd4F6M1PoblAvPS1zMDFOwG0>NH[zRmcxNTZiZB?=MkPYSG1UVw>?NIDaOpJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{MWWyOVA3Pzd6Nx?=
A498NUK4OJk6S2WubDDWbYFjcWyrdImgRZN{[Xl?MX6wMlUuOTBizszNMWCwMVYh\A>?MojNSG1UVw>?MXTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzNEfsbZUzPTB4N{e4Oy=>
115MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>MV6wMlUuOTBizszNMorVNE03KGR?MmfCSG1UVw>?M4r2UolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?M{\a[lI2ODZ5N{i3
117MljvR4VtdCCYaXHibYxqfHliQYPzZZk>NXrycnFHOC53LUGwJO69VQ>?MoruNE03KGR?Mmj2SG1UVw>?NH3hd|BqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{MYSyOVA3Pzd6Nx?=
ACHNM3[wXWZ2dmO2aX;uJGF{e2G7NFjVZmExNjVxMT:1JO69VQ>?NY\RTJNVPDhiaB?=MWHEUXNQMn7ScIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF?M3[xblI2ODZ5N{i3
Caki-2NWHlPYoxTnWwY4Tpc44hSXO|YYm=MkX6NE42NzFxNTFOwG0>NGr6Z5I1QCCqMmHiSG1UVw>?M{C1c4xm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJzMYWyOVA3Pzd6Nx?=
A498MlixSpVv[3Srb36gRZN{[Xl?NV\sOIRGOC53L{GvOUDPxE1?M172dlQ5KGh?NYHMfGFiTE2VTx?=NGPYNnJt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?=NXPofZQ6OjVyNke3PFc>
115Ml\iSpVv[3Srb36gRZN{[Xl?M332ZlAvPS9zL{Wg{txOMlHrOFghcA>?MXfEUXNQMlXycIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF?MnTHNlUxPjd5OEe=
ACHNNEjPOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXIdo02KM7:TR?=MYe0PEBpMWrEUXNQNULhN202cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKhMVWyOVA3Pzd6Nx?=
Caki-2NGPJXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYS1JO69VQ>?MnvUOFghcA>?NXrRSmozTE2VTx?=NULuTpZCcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKhM33tXFI2ODZ5N{i3
A498MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TuS|Uh|ryPMl71OFghcA>?NHjFcG9FVVORMlzrbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMgNEHjSVEzPTB4N{e4Oy=>
115M{DZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1f4OVUh|ryPNUPOSWRlPDhiaB?=NYHjOXZKTE2VTx?=MoK1bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMgMWSyOVA3Pzd6Nx?=
ACHNNGnzNGpHfW6ldHnvckBCe3OjeR?=MXe1JO69VQ>?M3vLXVQ5KGh?MmrMSG1UVw>?MnztbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?=Mn3JNlUxPjd5OEe=
Caki-2M4jKSWZ2dmO2aX;uJGF{e2G7MUS1JO69VQ>?NFzNWVg1QCCqNXHTWHhnTE2VTx?=Mm\jbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?=NXL5[WtxOjVyNke3PFc>
A498MmSySpVv[3Srb36gRZN{[Xl?NVzic4hiPSEQvF2=MmTZOFghcA>?NXmxV4p[TE2VTx?=M2foSYlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC=MoHMNlUxPjd5OEe=
115NUG2R3JzTnWwY4Tpc44hSXO|YYm=MUG1JO69VQ>?NITaO401QCCqNX3sXJFOTE2VTx?=NH\Ke2hqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMgNU\5ellIOjVyNke3PFc>
MOLM-13NGO0cFVHfW6ldHnvckBCe3OjeR?=NFOxN|E3yqEQvF2=MWKwMVghcA>?NYDsV|M4TE2VTx?=NYDJdZlbcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV|NH;jOJgzPDh6NUC4Ni=>
MOLM-13MXjGeY5kfGmxbjDBd5NigQ>?Mm\lOuKh|ryPMnHsOkBpNF7HSGZFVVORMofK[Y5p[W6lZYOgeIhmKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFJDKGGwZDDo[YF1KHOqb3PrJJBzd3SnaX7zJGh{eDJ5IHHu[EBJe3B7MB?=NWSxd2REOjR6OEWwPFI>
HepG2NXzkVXk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULEeVRuPzJiaB?=MlTXSG1UVw>?NX;6SmtSUUN3ME2zOU45PiEEsTCyMlkh|ryPMY[yOFg5PDhyOR?=
HepG2/AsMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlroO|IhcA>?MW\EUXNQNXmxZ|NDUUN3ME22PE4yOyEEsTC5MlYh|ryPNYDYTI9KOjR6OES4NFk>
SMMC7721NEDxTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrXU2Y4OiCqMU\EUXNQMojpTWM2OD1|MT6yPEDDuSB2LkKg{txOMWCyOFg5PDhyOR?=
SMMC7721/AcMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml62O|IhcA>?NHr4UpRFVVORM1X0VGlEPTB;NUWuNlEhyrFiNT6wN{DPxE1?MkW1NlQ5QDR6MEm=
Huh-7MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\ve|czKGh?NIq2TZBFVVORM{XDbWlEPTB;M{OuPVYhyrFiMz65JO69VQ>?NXH4R2IxOjR6OES4NFk>
Hep3BNID6bWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjVZo9wPzJiaB?=MlrBSG1UVw>?NWPWTXBlUUN3ME2yNE4yQCEEsTCxMlg1KM7:TR?=MoHrNlQ5QDR6MEm=
HepG2NWG5e2dZSXCxcITvd4l{KEG|c3H5NXXZfFNNcW6mdXPld{BieG:ydH;zbZM>MW[yOFg5PDhyOR?=
SMMC7721NH7XR|JCeG:ydH;zbZMhSXO|YYm=NGPGNVNqdmS3Y3XzJIFxd3C2b4Ppdy=>MnT5NlQ5QDR6MEm=
Huh-7NEnGdJdCeG:ydH;zbZMhSXO|YYm=NWLadVdzcW6mdXPld{BieG:ydH;zbZM>MV[yOFg5PDhyOR?=
Hep3BM2DMZ2Fxd3C2b4Ppd{BCe3OjeR?=MWPpcoR2[2W|IHHwc5B1d3Orcx?=NFrUc4kzPDh6NEiwPS=>
U2OS M{P4TWZ2dmO2aX;uJGF{e2G7NV31TZMxOjBizszNM4HkPVI1KGh?M3e3Xolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe=MkDTNlQ5Pjd{NUm=
AML2NGizeXFCeG:ydH;zbZMhSXO|YYm=M33vVlIwOTBizszNMnTNNlQwPDhiaB?=NEDPTGxqdmS3Y3XzJIFxd3C2b4Ppdy=>NFHBTWszPDZ3OUe0PS=>
MOML13M2ToZWFxd3C2b4Ppd{BCe3OjeR?=NGDZTGUzNzFyIN88US=>MnPMNlQwPDhiaB?=M1zHVIlv\HWlZYOgZZBweHSxc3nzM1rlb|I1PjV7N{S5
AML2MmDPSpVv[3Srb36gRZN{[Xl?MXixNO69VQ>?MXSyM|QhcA>?MknJbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO=M4nMWFI1PjV7N{S5
AML3NFfhdYxHfW6ldHnvckBCe3OjeR?=MWGxNO69VQ>?NGrhbVQzNzRiaB?=MU\pcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?=NX7ITJVbOjR4NUm3OFk>
MOML13MXfGeY5kfGmxbjDBd5NigQ>?MUexNO69VQ>?NH\qfYgzNzRiaB?=NYLSTotJcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM>MoDJNlQ3PTl5NEm=
BeWoMUDGeY5kfGmxbjDBd5NigQ>?MXizNEDDvU1?M{LDcVI1KGh?NWm0eoVDcW6lcnXhd4V{KHB3MzygUYRuOixicEKxJIFv\CCSdX3hJIF1KHSqZTDwdo91\WmwIHzleoVtM3LEZ|I1PDl6MUW0
BeWoNGTtSYFCeG:ydH;zbZMhSXO|YYm=NFz0RpM{OCEEtV2=M{nFWlI1KGh?MW\pcoNz\WG|ZYOgZZBweHSxc3nzNWS2WVNuOjR2OUixOVQ>
OCIMn7iSpVv[3Srb36gRZN{[Xl?MVKxNEDPxE1?NYjnXpl1OjRiaB?=NX70fI85fXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;uMWGyOFQ4OzV4Mh?=
MOLMM3vYeWZ2dmO2aX;uJGF{e2G7MVixNEDPxE1?Mn3FNlQhcA>?NU\kXIs3fXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;uM1myd|I1PDd|NU[y
U2OS NEn3ZmJHfW6ldHnvckBCe3OjeR?=MVGyNEDPxE1?MUeyOEBpM4XsT4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5?NGP1d4UzPDN4NkCwOy=>
RKOMmTGSpVv[3Srb36gRZN{[Xl?NUPVeHFtOjBizszNM37kWVI1KGh?MkP3bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>?M2m4T|I1OzZ4MEC3
U2OS NYfsT4lbTnWwY4Tpc44hSXO|YYm=MkP0NlAh|ryPMVSyOEBpMWDpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?=MnfwNlQ{PjZyMEe=
RKOM{TaOmZ2dmO2aX;uJGF{e2G7MUSyNEDPxE1?NXOzPJdEOjRiaB?=M1LiZolv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;uNGKwe|MzPDN4NkCwOy=>
SMMC-7721 NWPscnhSS2WubDDWbYFjcWyrdImgRZN{[Xl?NWS3WnNlOS5{NT2yNEDPxE1?M3vFPVI1NzR6L{eyJIg>NGTJV41FVVORMoD2bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=M1[yUlI1Ojh4M{Gy
HuH-7M1\pdmNmdGxiVnnhZoltcXS7IFHzd4F6Moi2NU4zPS1{MDFOwG0>NHn6N2EzPC92OD:3NkBpNIjjdVJFVVORNHXQRXZqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=>NUji[Hd6OjR{OE[zNVI>
SMMC-7721 MknGRZBweHSxc3nzJGF{e2G7NE\mSlYzOCEQvF2=MV60PEBpM{PjW2ROW09?MmDBbY5lfWOnczDhdI9xfG:|aYO=NI\nNWQzPDJ6NkOxNi=>
HuH-7NIezcWlCeG:ydH;zbZMhSXO|YYm=M1rENlIxKM7:TR?=NHTrVJM1QCCqM3rlS2ROW09?MoHUbY5lfWOnczDhdI9xfG:|aYO=M4X2blI1Ojh4M{Gy
SMMC-7721 NUnSSGpbTnWwY4Tpc44hSXO|YYm=MYKxNEDPxE1?MmjiN|YhcA>?NYC1c5JoTE2VTx?=MUnkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=>MnvaNlQzQDZ|MUK=
HuH-7NGS5epNHfW6ldHnvckBCe3OjeR?=M3nwNlExKM7:TR?=MWezOkBpMmjWSG1UVw>?NIDHeHJld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>?MW[yOFI5PjNzMh?=
AT2NVPOZ4tCTnWwY4Tpc44hSXO|YYm=M1e3WlUwOTBizszNNGq0[mJt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?=M4Tld|I1OjRyMkCz
REHNGPM[lRHfW6ldHnvckBCe3OjeR?=MoDDOU8yOCEQvF2=MljwcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB?NH;UbmEzPDJ2MEKwNy=>
UoCB6NYLldGJITnWwY4Tpc44hSXO|YYm=NYD0WodWPS9zMDFOwG0>NVS3Rpl1dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC=MY[yOFI1ODJyMx?=
AT2Mn:5R4VtdCCYaXHibYxqfHliQYPzZZk>NF7LNXMxNTJ3IN88US=>M3W0N4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?M1TiOVI1OjRyMkCz
REHNHnL[4VE\WyuIG\pZYJqdGm2eTDBd5NigQ>?M37B[|AuOjVizszNMnHpbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?M{Kw[lI1OjRyMkCz
UoCB6M1zJWGNmdGxiVnnhZoltcXS7IFHzd4F6NYqycGpEOC1{NTFOwG0>MmrSbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?NGHIcoszPDJ2MEKwNy=>
A2780MoXkSpVv[3Srb36gRZN{[Xl?NGexUGo2NzFyL{KwJO69VQ>?NYjPRWFEOjRiaB?=MnHTeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB?Ml6zNlQyOzZzNEe=
H460NU\5OYV2TnWwY4Tpc44hSXO|YYm=NWLONJNXPS9zMD:yNEDPxE1?NFm1Vm0zPCCqNWrRWFFIfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC=M2HyN|I1OTN4MUS3
Lovo NEHQSZJHfW6ldHnvckBCe3OjeR?=NHTUUZY2NzFyL{KwJO69VQ>?MXiyOEBpNFrmNWJ2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?=NGrLNI8zPDF|NkG0Oy=>
A2780NI\ZRZBCeG:ydH;zbZMhSXO|YYm=NV;LRXp3PS9zMD:yNEDPxE1?NI\QNVgzPCCqNVWzTYRq\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx?M{XQWVI1OTN4MUS3
H460NV\0bGZVSXCxcITvd4l{KEG|c3H5MUe1M|ExNzJyIN88US=>M1rxOFI1KGh?M2\tSIVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlNNG\QXnUzPDF|NkG0Oy=>
Lovo NVH3NWJ4SXCxcITvd4l{KEG|c3H5M3LLZ|UwOTBxMkCg{txONHjyXWszPCCqNGrGUZVmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>?MnT4NlQyOzZzNEe=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Biacore study Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate

Cell Assay: [1]

Cell lines HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
Concentrations Dissolved in DMSO, final concentrations ~ 30 μM
Incubation Time 8, 24, and 48 hours
Method Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.

Animal Study: [1]

Animal Models Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
Formulation Formulated in 2% Klucel, 0.5% Tween 80
Dosages 200 mg/kg
Administration Orally, twice a day

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Vassilev LT, et al. Science, 2004, 303(5659), 844-848.

[2] Thompson T, et al. J Biol Chem, 2004, 279(51), 53015-53022.

view more

Chemical Information

Download Nutlin-3 SDF
Molecular Weight (MW) 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one

Customer Product Validation (3)


Click to enlarge
Rating
Source Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck
Method Western Blot
Cell Lines UKF-NB cells
Concentrations 10 uM
Incubation Time 24 h
Results Only one study has reported an A76T mutation that was found in benign breast tissue. Interestingly, UKF-NB-3’RITA10 uM IV cells were as sensitive to nutlin-3 treatment as parental UKF-NB-3 cells with nutlin-3 treatment resulting in the induction of p53 response gene expression in these cells.

Click to enlarge
Rating
Source Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck
Method Caspase-Glo 3/7 Assays
Cell Lines UKF-NB-3 cells, UKF-NB-3r cells
Concentrations 10 μM
Incubation Time
Results Investigation of caspase 3/7 activation in response to Nutlin-3 and other cytotoxic drugs revealed that apoptosis induction is reduced and delayed in UKF-NB-3rNutlin10μM cells compared with UKF-NB-3 (Figure 2).

Click to enlarge
Rating
Source Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck
Method Immunoprecipitation
Cell Lines Hepatoma cells
Concentrations 20 uM
Incubation Time 24 h
Results It conducted in vivo ubiquitination assays with the treatment of Nutlin-3, a small molecule inhibitor of the MDM2/p53 interaction, and found that BIRC6 knockdown still facilitated the degradation of p53 by ubiquitination independent of Mdm2.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Mdm2 Products

  • Idasanutlin (RG-7388)

    Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • NSC 207895

    NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

  • Nutlin-3a

    Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

    Features:Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

  • Nutlin-3b

    Nutlin-3b is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.

  • YH239-EE

    YH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

Recently Viewed Items

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us